anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methylergonovine maleate acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.

Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60%, with no accumulation after repeated doses. During delivery with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver. 

Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid, with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of methylergonovine maleate solution was about 25% greater than the tablet. The volume of distribution (VdSS/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic, with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (Tmax about 3 hours) of methylergonovine maleate tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.
Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.
The invention discloses a composition of pure traditional Chinese medicine cream for curing hyperplasia of mammary glands and a preparation method thereof. The compound cream is oil-in-water type cream which is prepared from ethanol water extract solution of Chinese stellera root, zedoary, selfheal, radix salviae miltiorrhizae, angelica sinensis and turmeric as a raw material. Oil-phase raw materials include hexadecyl alcohol, albolene, glycerin monostearate and PEG-8 beewax, and water-phase raw materials include sodium lauryl sulfate, glycerine and distilled water. Tests prove that the cream has prevention and treatment effects on hyperplasia of mammary glands. The cream has a simple process, is exquisite and lubricant, has a good transdermal effect, and has no stimulation to the skin and allergy phenomenon, avoids the toxic or side effects of oral drugs, and is safe on clinical application. The cream has the reasonable composition, has the effects of promoting blood circulation to remove blood stasis, diminishing swelling to dredge collaterals, eliminating stagnation to stop pain and the like, and the efficacy is fast and directly reaches lesions. The cream is good medicine for curing hyperplasia of mammary glands.
BACKGROUND: Gastrointestinal parasite (GIP) infections are a major cause of global morbidity, infecting hundreds of millions of people each year and potentially leading to lifelong infection and serious complications. Few data exist on screening for GIP infections in migrants entering the UK or on the current performance of different traditional diagnostic approaches. This study aimed to describe the prevalence of GIP infections in Nepalese Gurkha recruits screened on arrival in the UK.
METHODOLOGY/PRINCIPAL FINDINGS: We present a retrospective analysis of data from screening male adults (18-21 years) who arrived in the UK from Nepal between 2012 and 2020. Three separate faecal samples were obtained from participants at weekly intervals and processed for formalin-ethyl acetate (FEA) concentration/light microscopy and charcoal culture. Serum samples were analysed for IgG antibodies to Strongyloides stercoralis by ELISA. Results were available from 2,263 participants, of whom 463 (20.5%, 95% CI 18.8%-22.2%) had a positive diagnostic test for at least one GIP infection. A total of 525 potential infections were identified. Giardia duodenalis was most common (231/2263, 10.2%), followed by S. stercoralis (102/2263, 4.5%), and hookworm species (86/2263, 3.8%). Analysis (microscopy and culture) of the initial stool sample diagnosed only 244/427 (57.1%) faecally identified pathogens, including 41/86 (47.7%) hookworm infections. The proportion of participants infected with any GIP showed a downward trend over the study period. Log-binomial regression showed risk of infection decreasing by 6.1% year-on-year (95% CI 3.2% - 9.0%). This was driven predominantly by a fall in hookworm, S. stercoralis and Trichuris trichiura prevalence.
CONCLUSIONS/SIGNIFICANCE: The level of potentially pathogenic GIP infection in young Nepalese men migrating to the UK is high (20.5%) and requires a combined diagnostic approach including serology and analysis of multiple stool samples incorporating specialised parasitological methods. Advances in molecular approaches may optimise and simplify the intensive screening strategy required.
Safety and effectiveness of CLINIMIX E in pediatric patients have not been established by adequate and well-controlled studies. Use of dextrose, amino acid infusions and electrolytes in pediatric patients is based on clinical practice [see Dosage and Administration (2.8)].

Deaths have occurred in neonates (28 days of age or younger) who received concomitant intravenous calcium-containing solutions with ceftriaxone resulting from calcium-ceftriaxone precipitates in the lungs and kidneys, even when separate infusion lines were used. CLINIMIX E is contraindicated in neonates receiving ceftriaxone [see Contraindications (4), Warnings and Precautions (5.2)].

Newborns, especially those born premature and with low birth weight, are at increased risk of developing hypo – or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death. Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

Because of immature renal function, preterm infants receiving prolonged treatment with CLINIMIX E, may be at risk of aluminum toxicity [see Warnings and Precautions (5.9)].

Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.10)].

Hyperammonemia is of special significance in infants (birth to two years). This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured frequently in infants [see Warnings and Precautions (5.8)].
Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) and is one of the leading causes of morbidity and mortality in patients with SLE. It is estimated that up to 60% of individuals with SLE will develop LN, which can manifest at any stage of a patient's life; however, it commonly emerges early in the course of SLE and tends to exhibit a more aggressive phenotype in men compared to women. Black and Hispanic patients are more likely to progress to kidney failure than white patients. LN is characterized by kidney inflammation and chronic parenchymal damage, leading to impaired kidney function and potential progression to kidney failure. This article provides a comprehensive overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and management of LN, highlighting the importance of early recognition and treatment of LN to prevent progressive, irreversible kidney damage and improve patient outcomes. Additionally, the article discusses current and emerging therapies for LN, including traditional immunosuppressive agents, biological agents, and novel therapies targeting specific pathways involved in LN pathogenesis, to provide a practical guide for clinicians in properly diagnosing LN and determining a patient-centered treatment plan.
PURPOSE:To obtain the titled preparation effectively preventing loss and inactivation of active caused by adsorption on a container wall, association, polymerization, oxidation, etc., containing a granulocyte colony stimulating factor (G-CSF) and a protein. CONSTITUTION:The titled preparation containing G-CSF and a pharmaceutically acceptable protein such as human serum albumin, human serum globulin, gelatin and acid treated gelatin having 7,000-100,000 average molecular weight. The preparation contains preferably 1-20,000pts.wt. protein based on 1pt.wt. G-CSF. Loss, reduction in activity, etc., of the active component can be effectively prevented, a dose of G-CSF as a component of very small amount can be extremely accurately controlled and expensive G-CSF can be effectively used.
Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be selected. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
Degenerative arthritis is a universal concomitant of human aging, affecting 51% of the adult population. Arthritis of the spine is the most common cause of acquired spinal cord dysfunction and can manifest in subtle symptoms, such as diminished balance and dexterity, or profound symptoms, such as paralysis and incontinence. In cases where dysfunction results in severe spinal cord compression, surgery is performed. However, surgical outcomes are not always beneficial. Past research has reported that approximately one-third of surgery patients improved, one-third remained the same and one-third worsened. Currently, there are no reliable tests that can predict outcome following surgery. We are hoping that this study will change that.

Twenty-five patients will undergo 45 minute imaging sessions pre-operatively and six months post-operatively. Ten controls will undergo 45 minute imaging sessions twice to provide a baseline comparison and reproducibility. During each session, one motor task (finger tapping) and 1 sensory task (hand brushing) will be performed for 2 minutes at 10 second intervals. We wish to compare the change in volume extent, and location, and intensity of brain activation levels before and after surgery. We will also compare fMRI signal response differences between controls and patients. We hypothesize that the degree to which brain activation shifts towards normalcy (that of controls) will correlate with the degree of neurological recovery postoperatively.

Data will be analyzed using software developed at the Robarts Research Institute.
PCT No. PCT/JP96/02374 Sec. 371 Date Jul. 18, 1997 Sec. 102(e) Date Jul. 18, 1997 PCT Filed Aug. 23, 1996 PCT Pub. No. WO97/08959 PCT Pub. Date Mar. 13, 1997The invention discloses a bait for fishes and shellfishes characterized in that the bait comprises a matrix material containing a microorganically fermented product of a plant residue obtained by separating from a plant at least one liquid selected from the group consisting of vegetable juice, fruit juice, plant essential oil, juice extracted from a processed plant product, plant milk and mixtures thereof, or disintegrated product of said microorganically fermented product, wherein the matrix material has incorporated therein (A) an amino acid having 2 or 3 carbon atoms, and (B) amino acid having at least 4 carbon atoms in an (A)/(B) molar ratio of 1:1 to 40:1.
BACKGROUND AND AIMS: The circadian pattern of eating behaviors has garnered increasing interest as a strategy for obesity prevention and weight loss. It is believed that the benefits stem from aligning food intake with the body's natural daily rhythms. However, the existing body of evidence is limited in scale and scope and there has been insufficient evaluation of temporal eating behaviors, such as the specific time of day in which the highest calorie consumption occurs, meal frequency, and distribution. This research aims to explore the association between the timing of the largest meal of the day and eating frequency with Body Mass Index (BMI) and obesity.
METHODS: Participants (n = 2050, 18-65y) were part of an exploratory cross-sectional and population-based research, with data collection in a virtual environment. Linear regression analyses and restricted cubic splines evaluated differences in BMI associated with independent eating variables [timing of the largest meal, number of meals/day (as continuous and categorical: ≤3 or >3/day), and each largest meal of the day (breakfast/lunch/dinner)]. Logistic regression models were fitted to assess Odds Ratios (OR) and 95 % Confidence Intervals (CI) of obesity associated with the same independent variables.
RESULTS: Our main findings were that the timing of the largest meal and reporting dinner as the largest meal were associated with higher values of BMI (respectively, 0.07 kg/m2 and 0.85 kg/m2) and increased odds of obesity [respectively OR(95%CI):1.04(1.01,1.08), and OR(95%CI):1.67(1.18,2.38)]. Those who realized more than 3 meals/day presented lower values of BMI (-0.14 kg/m2) and 32 % lower odds of having obesity [OR(95%CI):0.68(0.52,0.89)]. Reporting lunch as the largest meal also protected against obesity [OR(95%CI):0.71(0.54,0.93)]. These associations were statistically significant and independent of sex, age, marital status, education level, diet quality, sleep duration, and weekly frequency of physical exercise.
CONCLUSION: Having the largest meal earlier in the day, concentrating the majority of caloric intake during lunch, and consuming more than three meals a day, may present a promising intervention for preventing and treating obesity/overweight.
PURPOSE:To provide a cosmetic having excellent ultraviolet-shielding capability and transparent natural color, by using a compound oxide of a specific metal and zinc having an average particle diameter falling within a specific range as a component. CONSTITUTION:A compound oxide powder of Zn and a metal selected from Al, Fe, Cr, Ce, Zr and Ti and having an average particle diameter of 0.001-0.5mum, especially 0.005-0.2mum is used as a component of the cosmetic at an amount of 0.1-40wt%, especially 0.5-30wt%. All Zn atoms in the compound oxide are preferably bonded to the other metals via oxygen atom. The ratio of Zn to the other metal depends upon the kind of the metal and is 0.001-0.5 for Al and 0.01-0.25 for Ti per 1pt. of Zn. The compound oxide powder has an ultraviolet-shielding capability of >=90% to ultraviolet ray of <=400nm wavelength and a transmittance of >=60% for visible light and near infrared radiation (400-3,000nm wavelength) and does not deteriorate organic materials contacting the oxide.
Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
The medical records system includes a medical records database used to store medical record information for a patient. The system provides a graphical user interface from which the patient can enter, update and store their medical records information. The graphical user interface can be part of a client terminal at a local network site. A computer network, such as the Internet, or other wide area network configuration, can be used to implement the medical records system. In particular, the medical records database can be accessed by the client terminal from any location via the computer network providing a mechanism for accessing patient medical records information from any location. In this way, the medical history of the patient is maintained constant, up-to-date and made available for future access both by the patient and the physician.
The invention discloses a traditional Chinese medicine preparation for treating chronic nephritis. The traditional Chinese medicine preparation comprises a preparation A, a preparation B and a preparation C. The preparation A comprises 15-25g of leech, 35-45g of cinnabar, 5000ml of white spirit and 3000ml of ethanol having the content of 95%. The preparation B comprises 4-6g of notopterygium root, 2-4g of pubescent angelica root, 4-6g of divaricate saposhnikovia root, 1.5-2.5g of ephedra and 4-6g of cassia twig. The preparation C comprises 480-520g of stir-fried folium artemisiae argyi, 90-110g of borneol, 45-55g of camphor, 230-270g of stir-fried Chinese prickly ash, 8-12g of centipede and 28-32g of scorpion. In treatment, a fire treatment method and a moxibustion treatment method are combined. Through the combination of the fire treatment method and the moxibustion treatment method, the traditional Chinese medicine preparation can cure chronic nephritis after 1-3 treatment courses and avoid recurrence, wherein the treatment course comprises 30 days.
Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Women with very high mammographic density have a four to six fold higher breast cancer risk than women with low mammographic density. At the same time, the sensitivity of mammography is seriously impaired in women with high mammographic density, leading to many missed cases. Nevertheless, in the Netherlands this high risk group is currently screened between the age of 50 and 75 years with mammography only. MRI is likely to lead to better detection of breast tumors in women with high mammographic density, because it has a much higher sensitivity than mammography. The DENSE trial investigates the additional value of MRI for breast cancer screening in this risk group. Participants with extremely dense breasts (ACR4) and a negative mammogram are randomized to 'additional MRI' (n=7,237) versus 'current practice' (n=28,948).
PURPOSE: Cosmetic composite powder with a multilayered structure, and a method for manufacturing the same are provided to block UV rays, shield skin, and to dilute pigments. CONSTITUTION: Cosmetic composite powder with a multilayered structure comprises a basal layer, an optical layer, and a coloring layer. The basal layer is formed of plate powder. The optical layer is fixed on the basal layer by physical pressurization, and contains titanium dioxide. The coloring layer is fixed on the surface of the optical layer by physical pressurization. A method for preparing the cosmetic composite powder comprises: a step of preparing the plate powder; a step of fixing the titanium dioxide on the basal layer by physical pressurization; and a step of fixing ferric oxide on the optical layer.
PURPOSE: A composition for improving sexual function and a food containing the same are provided to improve sexual functional by vasodilation and hormone balance. CONSTITUTION: A composition for improving sexual function contains 30-70 weight% of Lepidium meyenii, 40-60 weight% of red ginseng, and 20-40 weight% of Tribulus alatus extract as an active ingredient. The composition is fermented by adding Lactobacillus(Leuconostoc sp., Lactobacillus sp., Lactococcus sp., Bifidobacterium sp., and Streptococcus sp.) only or together with a starter. A food for improving sexual function contains the extract as an active ingredient. The food includes gum, tea, vitamin complex, health supplement, and honey.
PURPOSE: To obtain an anticancer agent containing the antibiotic RS-44 as an active ingredient and capable of exhibiting growth inhibiting action on various kinds of leukemia bacterial in an extremely low concentration. CONSTITUTION: This agent is obtained by including the antibiotic RS-44 as an active ingredient, mixing the active ingredient with a surfactant, a vehicle, a lubricant, a film-forming substance, etc., and preparing the mixture. The anticancer agent can be prepared in a form of capsules, tables, granules, particles, powder, suspension, injection, drops, etc., and can orally or parenterally be administered. The daily dose is about 0.01-5mg/Kg adult body in the case of oral administration and the upper limit of the daily dose is about 0.5mg/kg adult body in the case of parenteral administration. The antibiotic RS-4 is obtained by inoculating a microorganism belonging the genus Streptomyces into a culture medium and culturing the microorganism, extracting the cultured product with ethyl acetate and concentrating and purifying the extracted solution.  The antibiotic has the physical characteristics as follows: property, white powder; decomposition point, >=160 deg.C; elemental analysis value: C 63.36%, H 8.69%, O 26.72%; molecular formula, C42 H70 O12 ; and molecular weight, 766 (FD mass spectrum).
Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.